PANS and PANDAS Research & Advocacy News

Welcome to the PACE Foundation newsroom! Stay updated on the latest breakthroughs in PANS and PANDAS treatment updates, pediatric clinical trials, and CPAE community updates. We provide evidence-based news to help families and physicians navigate neuropsychiatric disorders with the most current research available.

Official Recognition: PANS Joins PANDAS on the NIH Rare Disease List

By PACE Foundation | May 12, 2026 |

Big news for our community! We are thrilled to share that the Genetic and Rare Diseases Information Center (GARD), which is managed by the National Institutes of Health (NIH), has officially added Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) to its list of rare diseases. If you’ve been in this fight for a while, you know how…

PANS/PANDAS Insurance Mandates: A State-by-State Guide to Your Rights

By PACE Foundation | Apr 17, 2026 |

If you are reading this, you likely know the heart-shattering experience of watching your child change overnight. One day they are themselves: happy, curious, and thriving: and the next, they are grappling with a sudden onset of severe anxiety, OCD, tics, or personality changes. This is the reality of PANS/PANDAS (Pediatric Acute-onset Neuropsychiatric Syndrome and…

Major Win: Aetna Now Covers PANS and PANDAS Treatments (Including IVIG!)

By PACE Foundation | Mar 11, 2026 |

If you’ve ever spent hours on hold with an insurance company only to be told that your child’s life-altering symptoms are “behavioral” or “experimental,” take a deep breath. We have some news that might actually make you want to do a little happy dance in your kitchen (or at least exhale that breath you’ve been…

A Blueprint for PANS/PANDAS Care: New Landmark Paper from the U of A CPAE Center of Excellence

By PACE Foundation | Jan 15, 2026 |

For many families navigating the world of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS), the journey to a diagnosis is often marked by confusion and a sense of being unheard. At The PACE Foundation, we have spent over a decade working to change that narrative. Today, we…

PANZYGA IVIG Study Updates: Promising Results for PANS/PANDAS Research

By PACE Foundation | May 28, 2025 |

While the data from the IVIG trial is under review, we are pleased that Octapharma has officially released a statement regarding the IVIG trial. Below is an excerpt from their announcement:  “From baseline (week 0) to week 9, there was a mean improvement of 31.1% (SD 40.68) in the PANZYGA® group CY-BOCS score as compared…